Drugs / DCY636
last change Jun 2026 re-read 3 minutes ago

DCY636

Developed for
atopic eczema
Investigated by
Novartis Pharmaceuticals

Trials 1

20272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07604324 Jun 2026 → Jan 2028 expected atopic eczema Novartis Pharmaceuticals Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as DCY636 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07604324 ↗